Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index; 61 of the 118 sources its claims cite were checked for support.

Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies

Open access

Abstract

Obesity is a growing global health concern with widespread impacts on physical, psychological, and social well-being. Clinically, it is a major driver of type 2 diabetes (T2D), cardiovascular disease (CVD), non-alcoholic fatty liver disease (NAFLD), and cancer, reducing life expectancy by 5-20 years and imposing a staggering economic burden of USD 2 trillion annually (2.8% of global GDP). Despite its significant health and socioeconomic impact, earlier obesity medications, such as fenfluramine, sibutramine, and orlistat, fell short of expectations due to limited effectiveness, serious side effects including valvular heart disease and gastrointestinal issues, and high rates of treatment discontinuation. The advent of glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., semaglutide, tirzepatide) has revolutionized obesity management. These agents demonstrate unprecedented efficacy, achieving 15-25% mean weight loss in clinical trials, alongside reducing major adverse cardiovascular events by 20% and T2D incidence by 72%. Emerging therapies, including oral GLP-1 agonists and triple-receptor agonists (e.g., retatrutide), promise enhanced tolerability and muscle preservation, potentially bridging the efficacy gap with bariatric surgery. However, challenges persist. High costs, supply shortages, and unequal access pose significant barriers to the widespread implementation of obesity treatment, particularly in low-resource settings. Gastrointestinal side effects and long-term safety concerns require close monitoring, while weight regain after medication discontinuation emphasizes the need for ongoing adherence and lifestyle support. This review highlights the transformative potential of incretin-based therapies while advocating for policy reforms to address cost barriers, equitable access, and preventive strategies. Future research must prioritize long-term cardiovascular outcome trials and mitigate emerging risks, such as sarcopenia and joint degeneration. A multidisciplinary approach combining pharmacotherapy, behavioral interventions, and systemic policy changes is critical to curbing the obesity epidemic and its downstream consequences.

Overview

CoChat Summary

## TL;DR

This is a narrative review of obesity that synthesizes its biology, complications, and treatment landscape, with emphasis on recent incretin-based and other emerging therapies. It argues that modern drugs can produce large short-term weight loss, but long-term success still depends on sustained lifestyle support and broader access to care.

## Key findings

  • Obesity is presented as a major global health crisis, with prevalence “nearly tripling since 1975,” causing millions of avoidable deaths each year and an economic burden of “USD 2 trillion annually (2.8% of global GDP).”
  • The paper reports that newer GLP-1–based therapies have produced “15–25% mean weight loss” in clinical trials; it also states these agents reduced major adverse cardiovascular events by “20%” and T2D incidence by “72%.”
  • In STEP 1, semaglutide 2.4 mg weekly produced a mean placebo-adjusted weight loss of “14.9% over 68 weeks,” and up to “16.0%” in STEP 4 with continued use.
  • In SURMOUNT-1, tirzepatide 15 mg weekly achieved mean weight reductions of “20.9% over 72 weeks,” with “50–57%” of participants losing at least 20% of body weight; the review also cites retatrutide producing weight loss of “up to 24.2% over 48 weeks.”
  • For cagrilintide plus semaglutide, the phase 2 study reported mean body weight reductions of “15.6% at 32 weeks” versus “5.1%” with semaglutide alone; bimagrumab’s 48-week phase II trial is reported as reducing fat mass by “20.5%,” increasing lean mass by “3.6%,” and producing “6.5%” weight loss versus “0.8%” for placebo.

## Methods

  • Narrative review article that surveys obesity’s definition, risk factors, pathophysiology, historical treatments, new pharmacotherapies, and future directions.
  • The paper draws on previously published clinical trials, consensus definitions, and mechanistic studies; no original participant sample or new data collection is reported.
  • Main analysis is descriptive synthesis of the literature, comparing therapies by mechanism, route of administration, efficacy, and adverse effects.

## Limitations

  • The paper itself states that the review is limited by “high costs, supply shortages, and unequal access,” especially in low-resource settings, and by “gastrointestinal side effects and long-term safety concerns.”
  • It also states that weight regain after stopping medication is a major limitation, and that future research must prioritize long-term cardiovascular outcome trials and address risks such as sarcopenia and joint degeneration.
  • Evident from the text: this is not a systematic review or meta-analysis, so its conclusions depend on selected studies and reported trial results rather than a formal pooled analysis.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/medicines12030019

Cites

111 of 111 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Risk factors for obesity.
Figure 1 Risk factors for obesity.CC BY · PubMed Central
Figure 2 Complications of obesity. Legend: NASH = non-alcoholic steatohepatitis, NAFLD = non-alcoholic fatty liver disease, and PCOS = polycystic ovary syndrome.
Figure 2 Complications of obesity. Legend: NASH = non-alcoholic steatohepatitis, NAFLD = non-alcoholic fatty liver disease, and PCOS = polycystic ovary syndrome.CC BY · PubMed Central
Figure 3 Physiological effects of GLP-1, GIP, and amylin hormones on different organs. Legend: GLP = glucagon-like peptide, GIP = glucose-dependent insulinotropic polypeptide.
Figure 3 Physiological effects of GLP-1, GIP, and amylin hormones on different organs. Legend: GLP = glucagon-like peptide, GIP = glucose-dependent insulinotropic polypeptide.CC BY · PubMed Central

Verification

Claims the paper makes

51 Valid · 9 Not valid · 49 Not checked · 19 Own results and interpretations

40 more claims · 16 with their cited sources checked

Create a free account to see all 128 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 77
  • Probably not a substantial claim. 12

Create a free account to see these claims.

Citations

Cites

Show all 110 references

Research works printed but not linked: 1

  1. Rasmussen, N. (2008). On Speed: The Many Lives of Amphetamine, New York University Press. Available online: https://psycnet.apa.org/record/2008-03283-000.

Cited by

See all 38

Metadata

Authors
Ullah, M. I., & Tamanna, S.
Affiliations
University of Mississippi Medical Center (US)
Corresponding author
Ullah, Mohammad Iftekhar
Venue
Medicines
Publisher
MDPI AG
Published
2025-07-28
Volume
12
Issue
3
Pages
19
ISSN
2305-6320 (ISSN-L)
OpenAlex
W4412699426
Cited by
38
References
110
Citations by year
2026: 34 · 2025: 4
FWCI
5.11
Type
journal article
Language
en
Open access
Locations
  • Medicines (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
obesity, obesity pharmacotherapy, GLP-1 receptor agonists, semaglutide, tirzepatide, retatrutide, weight loss, type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease, cancer risk, anti-obesity drugs, valvular heart disease, weight regain, sarcopenia, joint degeneration, obesity prevention policy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-02, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-02 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies. https://app.cochat.ai/papers/10.3390/medicines12030019
The paper
Ullah, M. I., & Tamanna, S. (2025). Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies. Medicines. https://doi.org/10.3390/medicines12030019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.